HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination.

Abstract
We present six patients with acute fulminant episodes of CNS inflammatory demyelination who responded to therapeutic plasmapheresis after failing a course of high-dose methylprednisolone administered IV. Neurologic improvement occurred in three of the patients following the second plasmapheresis. Dramatic improvement in motor function (four patients) and language (two patients) began within 2 to 14 days and persisted during the 6 to 35 months (mean, 15 months) of follow-up. Results of this uncontrolled study suggest that plasmapheresis in the absence of other immunosuppressive drugs may have a role in the treatment of severe episodes of inflammatory demyelination in a select subset of MS patients.
AuthorsM Rodriguez, W E Karnes, J D Bartleson, A A Pineda
JournalNeurology (Neurology) Vol. 43 Issue 6 Pg. 1100-4 (Jun 1993) ISSN: 0028-3878 [Print] United States
PMID8170550 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Methylprednisolone
Topics
  • Adult
  • Demyelinating Diseases (etiology, therapy)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Methylprednisolone (therapeutic use)
  • Middle Aged
  • Multiple Sclerosis (complications)
  • Plasmapheresis
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: